sunshinebiopharma.com (SBFM): Price-to-Projected Revenue Ratio
Sunshine Biopharma (SBFM) is managed by a team of scientists focused on R&D transparency. However, preclinical stages and liquidity shortages create risks of equity dilution. The current forward P/S ratio visualizes these fluctuations, and 0.10 becomes the new value of the indicator. Growth prospects rely on the development of protein synthesis inhibitors for drug-resistant patients via insurance reimbursements.
Analytical breakdowns for Sunshine Biopharma
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Total Debt to Capital Sunshine Biopharma|SBFM - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Sunshine Biopharma, Inc.|SBFM - Company Aggregate Debt|Debts to Book Capitalization Sunshine Biopharma, Inc.|SBFM - Long-Term Debt|Company Current Liabilities Sunshine Biopharma|Quick Ratio sunshinebiopharma.com
- business earnings and investment ratios data:
SBFM - Company Net Income|Projected Future Earnings Sunshine Biopharma|SBFM - Business Payback Period|Future Price to Earnings Sunshine Biopharma|SBFM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sunshine Biopharma, Inc.|SBFM - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Sunshine Biopharma|SBFM - Earnings per share for the trailing year|Quarterly EPS earnings growth sunshinebiopharma.com|SBFM - Earnings growth in current year|Net earnings per share growth forecast for next year Sunshine Biopharma
- sales volume and revenue indicators:
Fundamental company valuation:Sunshine Biopharma SBFM
Amid the restructuring of the Sunshine Biopharma (SBFM) drug portfolio and the optimization of R&D expenditures, the forward price-to-sales ratio becomes a key indicator of market expectations for future sales. This chart reflects the dynamic relationship between current market capitalization and expected annual revenue, allowing investors to assess the asset's degree of overheating or the long-term valuation trend of the business relative to its operational efficiency.
Competitor analysis
BeiGene - Forward Price-to-Revenue Multiple|Forward P/S Multiple Halozyme Therapeutics, Inc. HALO|RVMD - Price-to-Projected Revenue Ratio|AAPG (Ascentage Pharma Corp) - Market Cap to Projected Revenue|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|URGN - Market Cap to Expected Sales Ratio|BCAX (Bicara Therapeutics) - Forward P/S Multiple|PSNL: Forward Price to Sales|Forward P/S Multiple ERAS|Market Cap to Expected Sales Ratio Delcath Corp|Price-to-Projected Revenue Ratio Y-mAbs Therapeutics YMAB|AURA: Market Cap to Projected Revenue|Candel - Forward P/S Multiple|Market Cap to Future Revenue Ratio Accuray Inc|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|Actuate Therapeutics Inc - Forward Price to Sales|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio HURA|Forward P/S Multiple TARA|Market Cap to Expected Sales Ratio Fate Therapeutics Inc|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|TScan Therapeutics Inc (TCRX) - Market Cap to Future Revenue Ratio|CSBR - Price-to-Projected Revenue Ratio|Future Price to Revenue XBIT|CVM: Forward P/S Multiple|OS Therapies Inc. - Forward Price to Sales|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Forward P/S Multiple Artiva|Price-to-Projected Revenue Ratio Adlai Nortye Ltd. (ANL)|VERU (verupharma.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Tempest Therapeutics, Inc. TPST|XLO - Forward Price-to-Revenue Multiple|Enochian BioSciences - Forward P/S Multiple|MURA - Forward P/S Multiple|kairospharma.com (KAPA) - Price-to-Projected Revenue Ratio|OKUR - Market Cap to Expected Sales Ratio|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CRIS|Forward P/S Multiple APLM|THAR: Future Price to Revenue|Price-to-Projected Revenue Ratio Advanced Biomed ADVB|GNPX - Forward Price-to-Revenue Multiple|Calidi Bio - Forward P/S Multiple|Xenetic Biosciences (XBIO) - Forward Price-to-Revenue Multiple|SLRX: Forward P/S Multiple|Kitov Pharma (PPBT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio American Oncology Network Inc|Market Cap to Projected Revenue BGNE (beigene.com)|Forward P/S Multiple CKPT|Forward Price-to-Revenue Multiple elevationoncology.com ELEV|Forward P/S Multiple ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Market Cap to Future Revenue Ratio|NTBL - Price-to-Projected Revenue Ratio|Forward Price to Sales VIRX (Viracta Therapeutics)|MOR (MorphoSys) - Forward Price-to-Revenue Multiple|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
